# DESCRIPTION

## FIELD OF THE INVENTION

- relate to methods and products for rheumatoid arthritis treatment

## BACKGROUND TO THE INVENTION

- define rheumatoid arthritis
- describe joint inflammation and systemic manifestations
- discuss disease prevalence and burden
- summarize diagnosis and classification criteria
- describe treatment aims and disease modifying anti-rheumatic drugs
- discuss biologic agents and their mechanisms
- describe remission and drug-free remission
- highlight lack of biomarkers for predicting drug-free remission

## SUMMARY OF CERTAIN EMBODIMENTS OF THE INVENTION

- identify novel biomarkers of drug-free remission
- describe method of determining likelihood of maintaining remission
- outline method of treating or preventing RA
- describe therapeutic agent for use in treating or preventing RA
- detail assay for detecting biomarkers
- specify biomarkers and their detection
- describe kit for carrying out methods and assays

## Example 1—Study Design

- define inclusion and remission criteria
- describe DAS28-CRP scoring system
- motivate use of CRP
- explain DAS28-CRP threshold
- outline study design and sample size estimation
- describe patient recruitment and DMARD cessation
- detail research blood tests and US scan schedule
- outline rescue glucocorticoids and DMARD therapy
- describe patient discharge criteria
- introduce prospective clinical variable assessment
- list pre-specified clinical variables
- describe Health Assessment Questionnaire Disability Index
- introduce retrospective clinical variable assessment
- list pre-specified variables for retrospective assessment
- describe systematic methodology for recording clinical variables
- outline assessment of RA criteria
- describe healthy control participants
- detail blood donation schedule for healthy participants
- introduce CD4+ T cell isolation
- describe CD4+ T cell isolation protocol
- detail CD4+ T cell lysis
- describe peripheral blood mononuclear cell isolation
- outline PBMC isolation protocol
- describe serum separation
- detail cell counting
- introduce CD4+ purity check by flow cytometry
- describe flow cytometry protocol
- introduce CD4+ T cell RNA extraction
- describe RNA extraction protocol
- introduce next-generation RNA sequencing
- describe RNAseq processing
- detail RNAseq library preparation
- describe RNAseq sequencing
- introduce multiplex cytokine/chemokine electrochemiluminescence assays
- describe serum sample preparation
- outline electrochemiluminescence assay protocol
- introduce data analysis
- describe data quality assessment
- outline data summarization and visualization
- introduce univariate Cox regression analysis
- describe multivariate Cox regression model building
- outline backward stepwise variable selection
- introduce patient dichotomization by variable levels
- describe composite score calculation
- outline survival curve comparison

### Example 2—Clinical Data Results

- identify predictive variables
- describe patient recruitment
- present patient outcomes
- perform survival analysis
- assess proportionality of hazards
- perform multivariate Cox regression
- identify associated variables
- create composite clinical biomarker score
- evaluate predictive value
- discuss baseline predictors
- discuss ACR/EULAR Boolean remission

## SUMMARY

- associate remission with flare

## Example 3—Cytokine Results

- introduce cytokine results
- motivate biomarker development
- describe sample collection
- detail quality control measures
- explain calibrator coefficient of variation
- calculate limits of detection
- handle samples below LLOD
- exclude assays with high LLOD
- perform logarithmic data transformation
- equilibrate plate data
- exclude assays with poor plate correlation
- perform baseline survival analysis
- identify associated cytokines
- perform multivariate Cox regression
- select variables for multivariate model
- confirm proportionality of hazards
- summarize distributions of cytokines
- perform ROC analysis
- determine biomarker thresholds
- create composite scores
- evaluate predictive value of composite scores
- perform sensitivity analysis for time to centrifugation
- assess effect of centrifugation delay
- compare cytokine levels at baseline and flare
- identify cytokines with significant changes
- compare cytokine levels at baseline and month six
- explore longitudinal change in cytokines
- describe longitudinal trends in CRP and SAA
- describe longitudinal trends in IL-6
- describe longitudinal trends in IL-27
- discuss implications of IL-27 results
- discuss implications of IL-6 results
- discuss implications of IP-10 results
- summarize longitudinal cytokine data
- discuss mechanisms underlying RA flare
- discuss immune homeostasis in DFR
- discuss role of IL-6 in RA pathogenesis
- discuss role of IL-12 in RA pathogenesis
- summarize cytokine results

### Example 4—CD4+ T Cell RNAseq Results

- introduce CD4+ T cells
- describe patient samples
- report CD4+ T cell RNA availability
- detail time from blood draw to processing
- detail time from processing to freezing
- report cell yield
- report CD4+ T cell purity
- describe healthy controls
- detail healthy control sampling
- report healthy control time from blood draw to processing
- report healthy control time from processing to freezing
- report healthy control cell yield
- report healthy control CD4+ T cell purity
- compare patient and healthy control yields
- compare patient and healthy control purity
- report RNA yield and integrity
- detail RNA sequencing quality
- describe baseline analyses
- detail gene expression analysis
- report differentially expressed genes
- describe univariate Cox regression
- report genes associated with time-to-flare
- describe multivariate Cox regression
- report final stepwise multivariate Cox model
- describe ROC analysis
- report biomarker utility
- describe composite score
- report sensitivity analysis
- discuss baseline comparison of flare vs. drug-free remission patients
- describe flare patients—flare vs. baseline visits
- report differentially expressed genes in flare patients
- describe DFR patients—month six vs. baseline visits
- report differentially expressed genes in DFR patients
- discuss IL-10 expression
- describe predictive biomarker survival analysis
- report univariate Cox regression results
- report multivariate Cox regression results
- describe composite score
- report ROCAUC
- summarize results
- discuss longitudinal comparison of flare visit with baseline
- discuss baseline CD4+ T cell gene expression in flare patients vs. healthy controls
- summarize predictive performance of genes

### Example 5—Integrative Analysis

- motivate integrative analysis
- describe two-step variable reduction
- select baseline variables
- perform univariate Cox regression
- perform multivariate Cox regression
- assess proportionality of hazards
- perform stepwise backward selection
- select final variables
- perform ROC analysis
- create composite scores
- compare predictive performance
- select optimum threshold
- discuss results
- interpret composite score
- define terms
- describe scope of invention

